Editorial: Recent advances in ovarian stimulation, volume II
Frontiers in Endocrinology · 11.11.2026 · 17
DOI: 10.3389/fendo.2026.2041968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 11.11.2026. Verfasst von Panagiotis Drakopoulos und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ovarian stimulation is the part of an IVF/ICSI cycle over which we, as clinicians, have the most direct control. The gonadotropin dose, the way we suppress the pituitary, how we trigger final maturation and whether we add anything on top all influence how many oocytes we retrieve, how competent they are and, ultimately, the chance of a live birth. Still, a fair share of everyday stimulation practice is driven by habit or local preference rather than solid evidence, and the list of available add-ons keeps growing faster than the data supporting them.With this second volume of Recent Advances in Ovarian Stimulation we wanted to revisit each stage of the stimulation pathway, from pre-treatment and adjuvants to protocol selection, final oocyte maturation and luteal phase support. The 18 papers we received come from centres in Europe, Asia and Latin America. Most are large real-world cohorts, but the collection also includes systematic reviews, randomized trials and one animal study. Reading them side by side, three questions kept coming up: how well can we predict response, which protocol suits which patient, and which add-ons, if any, have earned a place in routine care?Tailoring the dose to the patient only works if response can be predicted, and here the randomized data have been somewhat humbling: individualising the starting dose on ovarian reserve markers seems to make treatment safer rather than more successful. Several groups in this Topic therefore looked at what can be added to baseline markers. Xin et al. developed a nomogram for poor ovarian response based on AMH, AFC, basal FSH and BMI; it discriminated well, but its calibration slipped in a later cohort from the same centre, a reminder of how much external validation is still needed. Using almost 10,000 antagonist cycles, Luo et al. described a non-linear relationship between serum FSH on stimulation day 7 and the number of oocytes, with no additional benefit above roughly 9.1 mIU/mL. Wang et al. looked at the latefollicular rise in progesterone and found that basal progesterone, estradiol and LH on the hCG day, and the number of oocytes were independent risk factors, whereas a higher BMI appeared protective. In their review, Xu et al. make the case for using static and dynamic markers together rather than relying on any single one.Where progestin-primed ovarian stimulation (PPOS) fits is still debated, and four papers approach it from different angles. In women aged 35 and above, Qi et al. found that the GnRH antagonist protocol gave more blastocysts and a higher live birth rate per transfer than PPOS (27.0% vs 18.7%). The other data are more reassuring. In a Brazilian population of mixed ethnicity, Ingold et al. saw no difference in euploidy rates between the two protocols, and Jimenez et al. reported that medroxyprogesterone acetate prevented a premature LH surge as well as cetrorelix in PGT-A and fertility preservation cycles, with similar outcomes and fewer injections. On balance, PPOS looks like a safe choice when all embryos are frozen, although its equivalence in older women is not yet settled. In a different direction, Wei et al. added clomiphene citrate or letrozole to an antagonist protocol in normal responders and reduced gonadotropin consumption without lowering clinical pregnancy rates, which matters wherever treatment costs limit access.Dual triggering is increasingly offered to poor responders, mostly on the basis of studies in mixed populations. Mercorio et al. restricted their analysis to 1,824 cycles in POSEIDON group 4 women and found neither more mature oocytes nor more live births with the dual trigger. In this group, age and AMH predicted the result; the type of trigger did not.Luteal phase support is covered by REMODEL, a pilot trial in which Roelens et al. randomized 150 women having an artificial-cycle frozen embryo transfer to oral dydrogesterone or vaginal micronized progesterone. The ongoing pregnancy rate was lower with dydrogesterone (31.1% vs 44.7%), but the difference did not reach statistical significance. Oral treatment is clearly more convenient, so the right dose in this setting deserves to be tested in an adequately powered trial.Add-ons remain one of the more contentious issues in our field, since many are widely offered and paid for with little high-quality evidence behind them. The papers in this Topic show the problem quite clearly. Zhang et al. suggest that the moment dexamethasone is started may matter, with early and midfollicular initiation linked to higher live birth rates. Acupuncture was studied in three papers. In a mouse model, Ma et al. found that electroacupuncture improved endometrial receptivity after ovarian hyperstimulation, possibly through vasopressin neurons in the suprachiasmatic nucleus and the restoration of clock-gene rhythms. The meta-analysis by Guo et al., pooling 22 trials in women with PCOS, associated acupuncture with higher pregnancy rates, although the certainty of the evidence was low to moderate. In the multicentre randomized trial of Su et al., however, acupuncture did not increase the number of oocytes in 140 poor responders, and the improvements in cleavage rate and basal FSH did not lead to more pregnancies or live births.Lu et al. reached a similarly cautious conclusion for Zishen Yutai Pill in PCOS: a possible benefit, supported mainly by evidence of low or very low certainty. Likewise, Fang et al. showed that intraovarian platelet-rich plasma improves ovarian reserve markers but not pregnancy rates. The picture is a familiar one, in which the apparent benefit tends to shrink as the study design becomes more rigorous.Finally, two papers deal with safety and with what patients go through. Meng et al. built an interpretable machine-learning model to estimate the risk of OHSS after oocyte retrieval (AUC 0.81), which at this stage should be regarded as exploratory. In a randomized trial, Em-eam et al. showed that nalbuphine was non-inferior to pethidine for pain relief during oocyte retrieval. Some lessons go beyond the individual studies. The first concerns how we define our populations. The dual-trigger study shows that a homogeneous POSEIDON group can give a different answer from the mixed cohorts that came before it, and the same probably holds for PPOS in older women. The second is that surrogate outcomes can mislead us. A higher AMH after PRP, or a few more oocytes, does not necessarily mean more babies, and cumulative live birth per started cycle should remain the outcome by which treatments are judged. Third, inexpensive parameters that we already measure, such as basal progesterone or day-7 FSH, can still improve daily decisions, provided the models built on them are properly calibrated and validated elsewhere.These findings sit well with the wider move in reproductive medicine towards more restraint with addons and more individualised stimulation. At the same time, most of the evidence presented here is retrospective, comes from single centres and is concentrated in a few health systems. What we need now are randomized trials comparing PPOS and antagonist protocols in older women, properly blinded trials of adjuvants, and multicentre validation of prediction tools for response and OHSS in more diverse populations.We would like to thank all the authors and reviewers, as well as the editorial office, for their work on this Research Topic. We hope it proves useful to colleagues as they adapt stimulation to the individual patient.
Zitieren
APA
Drakopoulos, P., & Lee, T. (2026). Editorial: Recent advances in ovarian stimulation, volume II. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2041968
Vancouver
Drakopoulos P, Lee T. Editorial: Recent advances in ovarian stimulation, volume II. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2041968
BibTeX
@article{Drakopoulos2026,
author = {Drakopoulos, Panagiotis and Lee, Tsung-Hsien},
title = {Editorial: Recent advances in ovarian stimulation, volume II},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2041968}
}
EUVIMED